



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

October 28, 2014 6:00 – 8:15 p.m.
***** Please note new times *****

- 1. Executive Session** **6:00 - 6:15**
 - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))

- 2. Introductions and Approval of DUR Board Minutes** **6:15 - 6:20**
(Public Comment Prior to Board Action)

- 3. DVHA Pharmacy Administration Updates** **6:20 - 6:30**
 - Updates

- 4. Medical Director Update** **6:30 - 6:35**
 - Clinical Programs Update
 - Prescriber Comments

- 5. Follow-up Items from Previous Meetings** **6:35 – 6:50**
 - Benzodiazepines
 - Buprenorphine & Buprenorphine/Naloxone (end of grandfathering)
 - Oxycodone IR/Hydromorphone IR

- 6. RetroDUR/DUR** **6:50 – 7:10**
 - Diazepam Daily Quantities/Prescribing for Alcohol Withdrawal
 - Sovaldi[®] (sofosbuvir) in Hepatitis C

- 7. Clinical Update: Drug Reviews** **7:10 – 7:50**
(Public comment prior to Board action)
 - Abbreviated New Drug Reviews**
 - Harvoni[®] (ledipasvir-sofosbuvir) Oral Tablet (initial discussion, no PDL decision)
 - Sitavig[®] (acyclovir) Buccal Tablet

 - Full New Drug Reviews**
 - Myalept[®] (metreleptin) Vial for Subcutaneous Injection
 - Zohydro[®] ER (hydrocodone bitartrate) Extended Release Oral Tablet (non-abuse deterrent formulation)
 - Zontivity[®] (vorapaxar) Oral Tablet

- 8. Therapeutic Drug Classes – Periodic Review** **7:50 – 8:00**
(Public comment prior to Board action)
- Anticoagulants - Oral
- 9. Clinical Update: New/Updated Clinical Guidelines** **8:00 – 8:00**
(Public comment prior to Board action)
- None
- 10. New Managed Therapeutic Drug Classes** **8:00 – 8:00**
(Public comment prior to Board action)
- None
- 11. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products** **8:00 – 8:10**
(Public comment prior to Board action)
- Antidepressants – step therapy requirements for non-preferred agents
 - Kalydeco[®] (ivacaftor) Oral Tablet (additional approved genetic mutations)
- Updates for 1/1/2015**
- Testosterone: Topical
- 12. General Announcements** **8:10– 8:15**
Selected FDA Safety Alerts
- Xolair[®] (omalizumab) - slightly higher risk of cardiovascular/cerebrovascular events
- 13. Adjourn** **8:15**